Aradigm Corporation (NASDAQ:ARDM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. “

Shares of Aradigm Corporation (ARDM) traded up 4.80% during trading on Tuesday, reaching $1.31. The company’s stock had a trading volume of 15,234 shares. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.61. The company’s market cap is $19.39 million. Aradigm Corporation has a 12-month low of $0.78 and a 12-month high of $7.19.

Aradigm Corporation (NASDAQ:ARDM) last issued its quarterly earnings data on Monday, May 15th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.18. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 1,515.94%. The company had revenue of $1.69 million for the quarter. On average, analysts anticipate that Aradigm Corporation will post ($1.10) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Aradigm Corporation (ARDM) Rating Increased to Hold at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/11/aradigm-corporation-ardm-rating-increased-to-hold-at-zacks-investment-research.html.

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Get a free copy of the Zacks research report on Aradigm Corporation (ARDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.